Aktienanalyse zu NU Skin Enterprises Inc (NUS)NUSNU Skin Enterprises Inc

Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its beauty & skincare solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lines and wrinkles, and oily skin and pores. Its health & wellness solutions include gut health, bone and joint health, brain health, energy and stamina, heart health, immunity support, and protein and fitness. It offers various beauty devices, including ageLOC LumiSpa, Nu Skin RenuSpa iO and Prysm iO. Its ageLOC LumiSpa includes products such as LumiSpa iO Superpower Kit, ageLOC Rose Gold LumiSpa iO, LumiSpa Rose Gold Accent Twin Pack, and others. It operates in the Consumer Non-Cyclicals sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

NU Skin Enterprises Inc is currently not a strong buy. The stock is priced at 4.85, which is significantly lower than its 200-day simple moving average of 7.549, indicating a bearish trend. Additionally, the forward P/E ratio is 5.9032, suggesting it may be undervalued compared to its earnings potential, but the recent net income drop to -249798000 in Q2 2026 raises concerns about profitability. The RSI is at 52.765, indicating neutral momentum, and the stock has a year-to-date change of -49.95%, reflecting significant underperformance. The main risk is the negative net margin of -78.03% in Q2 2026, which indicates ongoing financial struggles.

6 analysts cover NUS: 3 rate it Buy, 1 Hold and 2 Sell.